Last reviewed · How we verify
mOPV1
mOPV1 is a monovalent oral polio vaccine that provides immunization against poliovirus type 1 through oral administration of attenuated virus.
mOPV1 is a monovalent oral polio vaccine that provides immunization against poliovirus type 1 through oral administration of attenuated virus. Used for Prevention of poliomyelitis caused by poliovirus type 1.
At a glance
| Generic name | mOPV1 |
|---|---|
| Also known as | Monovalent type 1 oral poliovirus vaccine |
| Sponsor | Aga Khan University |
| Drug class | Live attenuated vaccine |
| Target | Poliovirus type 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
mOPV1 contains a live attenuated (weakened) poliovirus type 1 strain that replicates in the intestinal tract, stimulating both mucosal and systemic immune responses. This generates antibodies and cellular immunity against poliovirus type 1, providing protection against infection and disease. The oral route allows for convenient mass vaccination campaigns, particularly in resource-limited settings.
Approved indications
- Prevention of poliomyelitis caused by poliovirus type 1
Common side effects
- Vaccine-derived poliovirus (VDPV) shedding
- Mild gastrointestinal symptoms
- Fever
Key clinical trials
- Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh (PHASE2)
- Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines (PHASE1)
- Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study (PHASE4)
- Use of mOPV1 in Routine Immunization in Pakistan. (NA)
- Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3 (NA)
- Poliovirus Vaccine Trial in Bangladesh (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |